JPWO2018191479A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2018191479A5 JPWO2018191479A5 JP2019555854A JP2019555854A JPWO2018191479A5 JP WO2018191479 A5 JPWO2018191479 A5 JP WO2018191479A5 JP 2019555854 A JP2019555854 A JP 2019555854A JP 2019555854 A JP2019555854 A JP 2019555854A JP WO2018191479 A5 JPWO2018191479 A5 JP WO2018191479A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- tslp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 204
- 238000000034 method Methods 0.000 claims description 103
- 102000040430 polynucleotide Human genes 0.000 claims description 102
- 108091033319 polynucleotide Proteins 0.000 claims description 102
- 239000002157 polynucleotide Substances 0.000 claims description 102
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 claims description 72
- 239000000427 antigen Substances 0.000 claims description 60
- 102000036639 antigens Human genes 0.000 claims description 60
- 108091007433 antigens Proteins 0.000 claims description 60
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 claims description 48
- 208000006673 asthma Diseases 0.000 claims description 35
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims description 34
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 34
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims description 34
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims description 34
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims description 34
- 230000000295 complement effect Effects 0.000 claims description 34
- 150000001413 amino acids Chemical class 0.000 claims description 24
- 210000003979 eosinophil Anatomy 0.000 claims description 12
- 210000004027 cell Anatomy 0.000 claims description 11
- 208000037874 Asthma exacerbation Diseases 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 6
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 6
- 102000025171 antigen binding proteins Human genes 0.000 claims description 5
- 108091000831 antigen binding proteins Proteins 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 238000011260 co-administration Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000002327 eosinophilic effect Effects 0.000 claims description 4
- 229940125369 inhaled corticosteroids Drugs 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 claims description 4
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 4
- 229940127212 long-acting beta 2 agonist Drugs 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 4
- 238000013313 FeNO test Methods 0.000 claims description 2
- 206010036790 Productive cough Diseases 0.000 claims description 2
- 230000001022 anti-muscarinic effect Effects 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 230000001934 delay Effects 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 229940124624 oral corticosteroid Drugs 0.000 claims description 2
- 210000003802 sputum Anatomy 0.000 claims description 2
- 208000024794 sputum Diseases 0.000 claims description 2
- 229960000278 theophylline Drugs 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims 56
- 239000000203 mixture Substances 0.000 claims 54
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 229940127211 short-acting beta 2 agonist Drugs 0.000 claims 2
- 235000017274 Diospyros sandwicensis Nutrition 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 241000282838 Lama Species 0.000 claims 1
- 229940110339 Long-acting muscarinic antagonist Drugs 0.000 claims 1
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000004777 chromones Chemical class 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023080295A JP2023099233A (ja) | 2017-04-12 | 2023-05-15 | 抗ｔｓｌｐ抗体による喘息治療 |
| JP2024127900A JP2024150751A (ja) | 2017-04-12 | 2024-08-02 | 抗ｔｓｌｐ抗体による喘息治療 |
| JP2025147176A JP2025170430A (ja) | 2017-04-12 | 2025-09-04 | 抗ｔｓｌｐ抗体による喘息治療 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762484864P | 2017-04-12 | 2017-04-12 | |
| US62/484,864 | 2017-04-12 | ||
| US201762553575P | 2017-09-01 | 2017-09-01 | |
| US201762553477P | 2017-09-01 | 2017-09-01 | |
| US62/553,575 | 2017-09-01 | ||
| US62/553,477 | 2017-09-01 | ||
| PCT/US2018/027271 WO2018191479A1 (en) | 2017-04-12 | 2018-04-12 | Treatment of asthma with anti-tslp antibody |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023080295A Division JP2023099233A (ja) | 2017-04-12 | 2023-05-15 | 抗ｔｓｌｐ抗体による喘息治療 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020516647A JP2020516647A (ja) | 2020-06-11 |
| JP2020516647A5 JP2020516647A5 (https=) | 2022-11-22 |
| JPWO2018191479A5 true JPWO2018191479A5 (https=) | 2022-11-22 |
| JP7330896B2 JP7330896B2 (ja) | 2023-08-22 |
Family
ID=62092313
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019555854A Active JP7330896B2 (ja) | 2017-04-12 | 2018-04-12 | 抗ｔｓｌｐ抗体による喘息治療 |
| JP2023080295A Withdrawn JP2023099233A (ja) | 2017-04-12 | 2023-05-15 | 抗ｔｓｌｐ抗体による喘息治療 |
| JP2024127900A Pending JP2024150751A (ja) | 2017-04-12 | 2024-08-02 | 抗ｔｓｌｐ抗体による喘息治療 |
| JP2025147176A Pending JP2025170430A (ja) | 2017-04-12 | 2025-09-04 | 抗ｔｓｌｐ抗体による喘息治療 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023080295A Withdrawn JP2023099233A (ja) | 2017-04-12 | 2023-05-15 | 抗ｔｓｌｐ抗体による喘息治療 |
| JP2024127900A Pending JP2024150751A (ja) | 2017-04-12 | 2024-08-02 | 抗ｔｓｌｐ抗体による喘息治療 |
| JP2025147176A Pending JP2025170430A (ja) | 2017-04-12 | 2025-09-04 | 抗ｔｓｌｐ抗体による喘息治療 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10828365B2 (https=) |
| EP (1) | EP3609917A1 (https=) |
| JP (4) | JP7330896B2 (https=) |
| KR (2) | KR20240070727A (https=) |
| CN (1) | CN110573525A (https=) |
| AU (2) | AU2018253118B2 (https=) |
| BR (1) | BR112019021482A2 (https=) |
| CA (1) | CA3059364A1 (https=) |
| CL (1) | CL2019002897A1 (https=) |
| CO (1) | CO2019011462A2 (https=) |
| IL (1) | IL269791B (https=) |
| JO (1) | JOP20190243B1 (https=) |
| MX (1) | MX2019012158A (https=) |
| MY (1) | MY207509A (https=) |
| PE (1) | PE20200484A1 (https=) |
| PH (1) | PH12019502331A1 (https=) |
| SG (1) | SG11201909322VA (https=) |
| TN (1) | TN2019000289A1 (https=) |
| TW (2) | TW202523688A (https=) |
| UA (1) | UA130334C2 (https=) |
| UY (1) | UY37676A (https=) |
| WO (1) | WO2018191479A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6516925B2 (ja) * | 2015-09-09 | 2019-05-22 | ノバルティス アーゲー | 胸腺間質性リンパ球新生因子（ｔｓｌｐ）結合性抗体および抗体を使用する方法 |
| KR20240070727A (ko) * | 2017-04-12 | 2024-05-21 | 암젠 인크 | 항-tslp 항체를 이용한 천식의 치료 |
| EP3981788A4 (en) * | 2019-06-04 | 2023-03-22 | Jiangsu Hengrui Medicine Co., Ltd. | ANTIBODY CAPABLE OF BINDING THYMIC STROMAL LYMPHOPOIETIN AND ITS USE |
| JP7597784B2 (ja) * | 2019-07-11 | 2024-12-10 | タヴォテック バイオセラピューティクス （ホン コン） リミテッド | 胸腺間質性リンパ球新生因子（ｔｓｌｐ）受容体シグナル伝達に干渉する薬剤 |
| KR102809618B1 (ko) * | 2019-09-04 | 2025-05-16 | 바이오션, 인코포레이티드 | Tslp에 결합하는 항체 및 이의 용도 |
| LT4051708T (lt) * | 2019-10-28 | 2025-04-10 | Medimmune Limited | Užkrūčio liaukos stromos limfopoetiną (tslp) surišančių antikūnų sausų miltelių pavidalo vaisto formos ir jų panaudojimo būdai |
| CN114887053B (zh) * | 2019-11-29 | 2026-04-24 | 康诺亚生物医药科技（成都）有限公司 | 一种tslp相关病症治疗剂的开发和应用 |
| MX2022004919A (es) * | 2019-12-13 | 2022-05-16 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Anticuerpo anti-linfopoyetina estromal timica (tslp) y sus usos. |
| TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法 |
| EP4103235A1 (en) * | 2020-02-13 | 2022-12-21 | Amgen Inc. | Formulations of human anti-tslp antibodies and methods of treating inflammatory disease |
| US20230073888A1 (en) * | 2020-02-13 | 2023-03-09 | Amgen Inc. | Treatment of atopic dermatitis with anti-tslp antibody |
| EP4106811A1 (en) * | 2020-02-18 | 2022-12-28 | Amgen Inc. | Formulations of human anti-tslp antibodies and methods of using the same |
| CN113388035B (zh) * | 2020-03-13 | 2026-02-27 | 迈威(上海)生物科技股份有限公司 | 特异性针对人tslp的抗体及其应用 |
| WO2022117079A1 (zh) * | 2020-12-03 | 2022-06-09 | 江苏恒瑞医药股份有限公司 | 结合胸腺基质淋巴细胞生成素的抗体及其应用 |
| CN113501878B (zh) * | 2021-02-03 | 2022-12-02 | 北京智仁美博生物科技有限公司 | 针对人tslp的多种抗体及其用途 |
| CN114853888B (zh) * | 2021-02-05 | 2023-11-03 | 上海洛启生物医药技术有限公司 | 抗tslp纳米抗体及其应用 |
| KR20230152062A (ko) * | 2021-03-03 | 2023-11-02 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 항tslp 항체를 포함하는 의약 조성물 |
| PH12023552762A1 (en) * | 2021-04-19 | 2024-04-15 | Medimmune Ltd | An anti-tslp fab with improved stability |
| WO2022226339A1 (en) | 2021-04-23 | 2022-10-27 | Amgen Inc. | Anti-tslp antibody compositions and uses thereof |
| KR20230175245A (ko) | 2021-04-23 | 2023-12-29 | 암젠 인크 | 변형된 항-tslp 항체 |
| CN113683694B (zh) * | 2021-09-03 | 2022-05-13 | 江苏荃信生物医药股份有限公司 | 一种抗人tslp单克隆抗体及其应用 |
| CN117106084B (zh) * | 2021-12-02 | 2024-03-22 | 北京东方百泰生物科技股份有限公司 | 一种抗tslp的单克隆抗体、其抗原结合片段及其应用 |
| CN117327176A (zh) * | 2022-06-24 | 2024-01-02 | 南京融捷康生物科技有限公司 | 一种抗tslp的单域抗体及其用途 |
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
| TW202426485A (zh) | 2022-10-26 | 2024-07-01 | 美商安進公司 | 抗ｔｓｌｐ抗體組成物及其用途 |
| TW202523697A (zh) * | 2023-08-25 | 2025-06-16 | 美商普羅特歐拉吉克適美國公司 | 抗ｔｓｌｐ抗體構築體及其用途 |
| TW202525846A (zh) | 2023-08-25 | 2025-07-01 | 美商普羅特歐拉吉克適美國公司 | 抗ｉｌ—１３多特異性抗體構築體及其用途 |
| CN117551195B (zh) * | 2024-01-12 | 2024-04-09 | 杭州畅溪制药有限公司 | 靶向tslp的vhh纳米抗体及其应用 |
| WO2025179220A1 (en) * | 2024-02-22 | 2025-08-28 | Flagship Pioneering Innovations Vi, Llc | Dosing of antigen binding molecules targeting thymic stromal lymphopoietin (tslp) |
| WO2025264860A2 (en) | 2024-06-18 | 2025-12-26 | Yale University | Methods of treating post-covid airway disease |
| US20260098100A1 (en) * | 2024-10-04 | 2026-04-09 | Prana Therapies, Inc. | Il-4r and tslp inhibitors and methods of use thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US7982016B2 (en) * | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
| UY32038A (es) | 2008-08-08 | 2010-03-26 | Glaxo Wellcome Mfg Pte Ltd | Inmunoblobulinas anti-cd127 y sus usos |
| PH12012500843A1 (en) | 2009-11-04 | 2019-07-10 | Merck Sharp & Dohme | Engineered anti-tslp antibody |
| AR082163A1 (es) | 2010-07-15 | 2012-11-14 | Hoffmann La Roche | Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos |
| US9100245B1 (en) | 2012-02-08 | 2015-08-04 | Amazon Technologies, Inc. | Identifying protected media files |
| US9306926B2 (en) | 2013-03-15 | 2016-04-05 | Brian A. Truong | User authentication using unique hidden identifiers |
| SG11201603127WA (en) * | 2013-10-23 | 2016-05-30 | Genentech Inc | Methods of diagnosing and treating eosinophilic disorders |
| EP3177322A4 (en) * | 2014-08-08 | 2018-07-18 | Alector LLC | Anti-trem2 antibodies and methods of use thereof |
| BR112017019412A2 (pt) * | 2015-03-11 | 2018-05-02 | Glaxosmithkline Ip Dev Ltd | proteínas ligadoras de tslp |
| AU2016320748B2 (en) * | 2015-09-09 | 2019-05-02 | Novartis Ag | Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies |
| KR20240070727A (ko) * | 2017-04-12 | 2024-05-21 | 암젠 인크 | 항-tslp 항체를 이용한 천식의 치료 |
-
2018
- 2018-04-12 KR KR1020247015858A patent/KR20240070727A/ko active Pending
- 2018-04-12 TN TNP/2019/000289A patent/TN2019000289A1/en unknown
- 2018-04-12 MY MYPI2019005927A patent/MY207509A/en unknown
- 2018-04-12 UA UAA201911056A patent/UA130334C2/uk unknown
- 2018-04-12 US US15/951,602 patent/US10828365B2/en active Active
- 2018-04-12 TW TW113133318A patent/TW202523688A/zh unknown
- 2018-04-12 KR KR1020197033043A patent/KR102666879B1/ko active Active
- 2018-04-12 JP JP2019555854A patent/JP7330896B2/ja active Active
- 2018-04-12 AU AU2018253118A patent/AU2018253118B2/en active Active
- 2018-04-12 EP EP18721605.6A patent/EP3609917A1/en active Pending
- 2018-04-12 WO PCT/US2018/027271 patent/WO2018191479A1/en not_active Ceased
- 2018-04-12 UY UY0001037676A patent/UY37676A/es not_active Application Discontinuation
- 2018-04-12 PE PE2019002026A patent/PE20200484A1/es unknown
- 2018-04-12 CA CA3059364A patent/CA3059364A1/en active Pending
- 2018-04-12 MX MX2019012158A patent/MX2019012158A/es unknown
- 2018-04-12 JO JOJO/P/2019/0243A patent/JOP20190243B1/ar active
- 2018-04-12 TW TW107112622A patent/TWI856945B/zh active
- 2018-04-12 IL IL269791A patent/IL269791B/en unknown
- 2018-04-12 BR BR112019021482-8A patent/BR112019021482A2/pt unknown
- 2018-04-12 SG SG11201909322V patent/SG11201909322VA/en unknown
- 2018-04-12 CN CN201880026131.3A patent/CN110573525A/zh active Pending
-
2019
- 2019-10-11 CL CL2019002897A patent/CL2019002897A1/es unknown
- 2019-10-11 PH PH12019502331A patent/PH12019502331A1/en unknown
- 2019-10-16 CO CO2019011462A patent/CO2019011462A2/es unknown
-
2020
- 2020-11-09 US US17/093,387 patent/US20210052726A1/en not_active Abandoned
-
2023
- 2023-05-15 JP JP2023080295A patent/JP2023099233A/ja not_active Withdrawn
-
2024
- 2024-08-02 JP JP2024127900A patent/JP2024150751A/ja active Pending
- 2024-10-08 US US18/909,660 patent/US20250032608A1/en active Pending
-
2025
- 2025-06-24 AU AU2025204735A patent/AU2025204735A1/en active Pending
- 2025-09-04 JP JP2025147176A patent/JP2025170430A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2018191479A5 (https=) | ||
| JP2024150751A5 (https=) | ||
| Menzella et al. | Tailored therapy for severe asthma | |
| AU2010248935B2 (en) | Methods and compositions for treating lupus | |
| JP7766392B2 (ja) | 治療用抗ｃｄ４０リガンド抗体 | |
| JP2022512722A (ja) | 抗ｃｄ３８抗体の皮下投与を提供する方法 | |
| JP2020536097A5 (https=) | ||
| JP2024502471A (ja) | ピーナッツアレルギーを治療するための方法およびｉｌ－４ｒアンタゴニストを投与することによってピーナッツアレルゲン特異的免疫療法を増強する方法 | |
| Amini-Vaughan et al. | Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer | |
| US20240287170A1 (en) | Methods for treating systemic sclerosis | |
| CN105705518A (zh) | 用于治疗类风湿性关节炎或作为镇痛药的中和gm-csf的抗体 | |
| JP2022500382A5 (https=) | ||
| JP2018533588A (ja) | 治療パラダイム | |
| WO2021213523A1 (zh) | 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途 | |
| JP2023505215A (ja) | Ｉｌ－３３アンタゴニストを投与することによりｃｏｐｄを治療するための方法 | |
| JP2023506779A (ja) | 慢性移植片対宿主病の処置用抗体 | |
| JPWO2019231983A5 (https=) | ||
| CN113993543B (zh) | 使用抗cd38抗体的组合疗法 | |
| TWI886758B (zh) | 抗pvrig/抗tigit雙特異性抗體在治療惡性腫瘤中的用途 | |
| CN115814076A (zh) | 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用 | |
| TW202206457A (zh) | 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體 | |
| HK40127073A (zh) | 使用抗ctla4抗体治疗胰腺癌的方法 | |
| JP2026503045A (ja) | Ｔｓｌｐ抗体を使用して喘息を治療するための方法 | |
| TW202529803A (zh) | 用於治療伴有多血管炎的嗜酸性球性肉芽腫病的ＩＬ－５Ｒ－α抗體 | |
| JPWO2022215054A5 (https=) |